GlassScriptPhysician profile
Elizabeth Altizer
NPI 1629565239
$1,480.03
in general payments reported to CMS, 2019-2025
14 companies · $443 in 2025
The $443 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $134 · 2023: $322 · 2024: $581 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.76 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $359.71 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $288.76 | 2024-2025 | Slynd |
| Medtronic, INC. | $131.55 | 2022-2024 | V-Loc 180 |
| Sumitomo Pharma America, INC. | $118.97 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $94.83 | 2023 | |
| Sage Therapeutics, LLC | $91.03 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $75.33 | 2022 | |
| Abbvie INC. | $65.95 | 2022-2024 | |
| Pfizer INC. | $57.81 | 2023-2024 | |
| Daiichi Sankyo INC. | $50.00 | 2022-2023 | Injectafer |
| Organon LLC | $49.75 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.92 | 2025 | |
| Boston Scientific Corporation | $35.91 | 2025 | General - Female Sui |
| Avion Pharmaceuticals | $13.51 | 2023 | Balcoltra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Altizer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.